TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02519530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Outreach Program
Description: The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
Study: NCT01366339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Study: NCT04318990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal radial artery access
Description: Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal radial artery surgery
Description: Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
Study: NCT03205410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: no - remote ischemic preconditioning
Description: The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
Study: NCT04342845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Motivational interviewing Placebo Comparator: Traditional lectures
Description: Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimental: Motivational interviewing Placebo Comparator: Traditional lectures
Description: Patients in the intervention group (n=117) received a four-session patient empowerment program in small groups over one month by trained nurses and doctors. he control group received traditional lectures that consisted solely of conveying healthcare information to patients.
Study: NCT02335164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin
Study: NCT00789243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
Study: NCT02335164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin
Study: NCT00764907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or orally during reinduction
Study: NCT02335164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant influenza hemagglutinin
Description: recombinant influenza hemagglutinin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax1
Description: Delta inulin adjuvant formulation 1
Study: NCT01399606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 5,10,20,or 40 mg per day, in a once daily scheme
Study: NCT03683615

Intervention type: PROCEDURE
Group type: OTHER
Intervention: repair of orbital floor fractures using resorbable plates
Study: NCT02633085

Intervention type: DEVICE
Intervention: Fixed Bearing or Mobile Bearing UKA
Description: Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
Study: NCT00764907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given intrathecally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV during reinduction
Study: NCT02303535

Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Description: All patients with congential and acquired heart disease treated by cardiac surgery procedures.

Intervention type: PROCEDURE
Intervention: Therapeutic cardiac catheterisations procedures
Description: All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
Study: NCT00764907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV during reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV during reinduction
Study: NCT00789243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
Study: NCT03098082

Intervention type: DEVICE
Group type: OTHER
Intervention: Actim Pancreatitis
Description: Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
Study: NCT01420965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011 (Anti-PD1 Antibody)
Description: Immune Enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011 (Anti-PD1 Antibody)
Description: Immune Enhancer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sipuleucel-T (Provenge)
Description: Vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (Provenge)
Description: Vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (Provenge)
Description: Vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Low dose- Immune Enhancer
Study: NCT00862732

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
Study: NCT02766361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Rehabilitation
Description: 12 weekly sessions of Combined intervention lasting 90 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
Study: NCT00862732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
Study: NCT00764907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine
Description: Given IV during reinduction
Study: NCT03821623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo pills twice a day for 3 months
Study: NCT00306644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: study drug
Study: NCT01990456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHASE 1: impact of tidal ventilation on VILI
Description: PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHASE 2: impact of PEEP on VILI
Description: PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
Study: NCT01735071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and trabectedin
Description: Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, trabectedin and carboplatin
Description: Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days
Study: NCT03867019

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability parameters monitoring
Description: No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate variability parameters monitoring
Description: No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~1. Dizziness Handicap Inventory (DHI) - hebrew version.~2. Stait-Trait Anxiety Inventory (STAI)
Study: NCT00357656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Description: An initial loading dose will be administered intravenously over a period \<= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always \>= 0.4 mL/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Description: The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period \<= 5 minutes (maximum infusion rate, 10 mL/min).
Study: NCT03623178

Intervention type: OTHER
Intervention: Assertive Community Treatment
Description: The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.

Intervention type: OTHER
Intervention: Treatment As Usual
Description: The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
Study: NCT01656629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20 mcg subq daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70 mg weekly for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium and vitamin D
Study: NCT02776033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
Study: NCT03433599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated exposure to acute Intermittent Hypoxia (rAIH)
Description: Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Room Air
Description: Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper-limb Training by Research Staff
Description: Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper-limb Training by Research Staff
Description: Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, gross grasping, fine grasping, and hand cycle using an arm ergometer. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-limb Training by Research Staff
Description: Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lower-limb Training by Research Staff
Description: Training sessions will last for approximately 30 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general leg/foot movement, over-ground walking, treadmill walking, stair climbing training, leg cycling, standing frame, and NuStep. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
Study: NCT03763942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMindr App
Description: Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control App
Description: Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
Study: NCT01807442

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview and Adherence
Description: All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview and Adherence
Description: All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
Study: NCT02335164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Advax1
Description: Delta inulin adjuvant formulation 1